

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(180) CA 125					16							16	15	94%
Samples and groups	[kU/L]													
Sample A		111	21	19	16							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	137	2,0	1,5	5	0	CVPG	135	1,7	20%	108	162	5	
Other					11	0							11	
								3x 4/12, 4x 4/60, 2x 4/149, 2x 4/179						
Sample B		14,1	3,2	23	16							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	16,0	1,8	11	5	0	CVPG	16,2	0,29	20%	12,9	19,5	5	
Other					11	0							11	
								3x 4/12, 4x 4/60, 2x 4/149, 2x 4/179						
(181) CA 15-3					15							15	13	87%
Samples and groups	[kU/L]													
Sample A		20,5	3,4	16	15							15	13	87%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	19,5	0,52	2,7	5	0	CVPG	19,4	0,29	18%	15,9	22,9	5	
Other					10	0							10	
								2x 4/12, 4x 4/60, 2x 4/149, 2x 4/179						
Sample B		32,5	6,5	20	15							15	13	87%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	33,7	2,1	6,2	5	0	CVPG	34	0,65	18%	27,8	40,2	5	
Other					10	0							10	
								2x 4/12, 4x 4/60, 2x 4/149, 2x 4/179						
(182) CA 19-9					17							17	15	88%
Samples and groups	[kU/L]													
Sample A		6,28	2,2	35	17							17	15	88%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	4,69	0,78	17	5	0	CVPG	4,6	0,16	±2,8	1,8	7,4	5	
Other					12	0							12	
								4x 4/12, 4x 4/60, 2x 4/149, 2x 4/179						
Sample B		147	150	99	17							17	16	94%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	340	40	12	5	0	CVPG	352	8,8	20%	281	423	5	
Other					12	0							12	
								4x 4/12, 4x 4/60, 2x 4/149, 2x 4/179						
(183) CA 72-4					15							14	12	86%
Samples and groups	[kU/L]													
Sample A		9,72	0,91	9,4	15							14	13	93%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	9,64	0,89	9,3	14	0	CVPG	10,1	0,19	20%	8,08	12,2	14	
Other					1	0							0	
								1x 1/185						
Sample B		2,94	0,37	12	15							14	12	86%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	2,98	0,34	11	14	0	CVPG	3,01	0,033	20%	2,4	3,62	14	
Other					1	0							0	
								1x 1/185						
(184) CYFRA 21-1					14							14	8	57%
Samples and groups	[µg/L]													
Sample A		18,9	1,7	9,2	14							14	13	93%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	19,1	2,2	12	10	0	CVPG	19	0,24	18%	15,5	22,5	10	
Other					4	0							4	
								4x 4/1						
Sample B		3,37	0,80	24	14							14	8	57%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	3,59	0,92	26	10	0	CVPG	3,47	0,10	18%	2,84	4,1	10	
Other					4	0							4	
								4x 4/1						
(185) AFP					16							16	12	75%
Samples and groups	[µg/L]													
Sample A		7,32	1,1	14	16							16	13	81%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	7,98	0,95	12	5	0	CVPG	7,5	0,084	20%	6	9	5	
Other					11	0							11	
								3x 4/1, 4x 4/12, 2x 4/149, 2x 4/179						
Sample B		65,1	11	16	16							16	14	88%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	72,4	9,3	13	5	0	CVPG	73,4	0,91	20%	58,7	88,1	5	
Other					11	0							11	
								3x 4/1, 4x 4/12, 2x 4/149, 2x 4/179						

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability							
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(186) hCG					17							17	14	82%
Samples and groups	[U/L]													
Sample A		17,2	1,7	10	17							17	15	88%
Other					17	0						17		
							2x 4/1, 4x 4/12, 3x 4/60, 2x 4/149, 2x 4/179, 4x 4/210							
Sample B		263	45	17	17							17	15	88%
Other					17	0						17		
							2x 4/1, 4x 4/12, 3x 4/60, 2x 4/149, 2x 4/179, 4x 4/210							
(189) CEA					17							17	14	82%
Samples and groups	[µg/L]													
Sample A		2,04	0,32	16	17							17	14	82%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		2,19	0,15	6,8	5	0	CVPG	2,27	0,036	16%	1,9	2,64	5	
Other					12	0						12		
							4x 4/12, 4x 4/60, 2x 4/149, 2x 4/179							
Sample B		35,3	5,1	14	17							17	16	94%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		39,4	0,74	1,9	5	0	CVPG	39,9	0,59	16%	33,5	46,3	5	
Other					12	0						12		
							4x 4/12, 4x 4/60, 2x 4/149, 2x 4/179							
(191) PSA					15							15	15	100%
Samples and groups	[µg/L]													
Sample A		8,29	1,5	18	15							15	15	100%
Other					15	0						15		
							4x 4/1, 3x 4/12, 4x 4/60, 1x 4/149, 2x 4/179, 1x 4/195							
Sample B		8,54	1,7	20	15							15	15	100%
Other					15	0						15		
							4x 4/1, 3x 4/12, 4x 4/60, 1x 4/149, 2x 4/179, 1x 4/195							
(194) NSE					13							13	13	100%
Samples and groups	[µg/L]													
Sample A		45,1	2,5	5,4	13							13	13	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		46,6	4,0	8,5	7	0	CVPG	43,2	0,49	30%	30,2	56,2	7	
(4) LIA (CLIA, CMIA, ECLIA); (259) Roche (3)		45,1	2,0	4,3	5	0	CVPG	43,1	1,1	30%	30,1	56,1	5	
Other					1	0						1		
							1x 3/24							
Sample B		10,4	5,6	54	13							13	13	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		13,8	2,1	15	7	0	CVPG	14,5	0,25	30%	10,1	18,9	7	
(4) LIA (CLIA, CMIA, ECLIA); (259) Roche (3)		4,79	0,72	15	5	0	CVPG	4,16	0,28	30%	2,91	5,41	5	
Other					1	0						1		
							1x 3/24							
(195) SCCA					8							8	8	100%
Samples and groups	[µg/L]													
Sample A		9,67	1,1	11	8							8	8	100%
Other					8	0						8		
							1x 3/24, 4x 4/1, 3x 4/60							
Sample B		2,06	0,53	26	8							8	8	100%
Other					8	0						8		
							1x 3/24, 4x 4/1, 3x 4/60							
(196) TPA					1							1	1	100%
Samples and groups	[U/L]													
Sample A		1650			1							1	1	100%
Other					1	0						1		
							1x 4/164							
Sample B		997			1							1	1	100%
Other					1	0						1		
							1x 4/164							
(198) free-PSA					10							10	10	100%
Samples and groups	[µg/L]													
Sample A		6,61	0,73	11	10							10	10	100%
Other					10	0						10		
							4x 4/1, 2x 4/12, 1x 4/60, 1x 4/149, 1x 4/179, 1x 4/195							
Sample B		6,84	0,58	8,5	10							10	10	100%
Other					10	0						10		
							4x 4/1, 2x 4/12, 1x 4/60, 1x 4/149, 1x 4/179, 1x 4/195							
(201) S-100					6							5	5	100%
Samples and groups	[µg/L]													
Sample A		0,095	0,007	7,8	6							5	5	100%
Other					6	0						5		
							1x 2/98, 4x 4/60, 1x 4/256							
Sample B		0,066	0,019	28	6							5	5	100%
Other					6	0						5		
							1x 2/98, 4x 4/60, 1x 4/256							

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

Test	[unit]					Comparability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(206) Calcitonin					3							3	2	67%
Samples and groups	[ng/L]													
Sample A		7,46	3,8	50	3							3	2	67%
Other					3	0						3		
							1x 1/24, 2x 4/29							
Sample B		7,24	0,87	12	3							3	3	100%
Other					3	0						3		
							1x 1/24, 2x 4/29							
(207) Thyreoglobulin					3							3	2	67%
Samples and groups	[µg/L]													
Sample A		109	15	14	3							3	3	100%
Other					3	0						3		
							1x 3/24, 2x 4/29							
Sample B		12,3	3,4	28	3							3	2	67%
Other					3	0						3		
							1x 3/24, 2x 4/29							
(208) beta-2-microglobulin					12							9	9	100%
Samples and groups	[mg/L]													
Sample A		1,47	0,17	12	12							9	9	100%
Other					12	0						9		
							1x 1/36, 1x 6/1, 2x 6/58, 1x 6/60, 1x 6/75, 1x 6/91, 4x 6/149, 1x 6/177							
Sample B		1,44	0,13	9,4	12							9	9	100%
Other					12	0						9		
							1x 1/36, 1x 6/1, 2x 6/58, 1x 6/60, 1x 6/75, 1x 6/91, 4x 6/149, 1x 6/177							

st_kn_p

End of report

Printed: 27.02.2019